Early experience with Levosimendan in children with ventricular dysfunction

Pediatric Critical Care Medicine

Volumn 7, Issue 5, 2006, Pages 445-448

  Namachivayam, Poongundran ^a   Crossland, David S ^a   Butt, Warwick W ^a   Shekerdemian, Lara S ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Children; Congenital heart disease; Heart failure; Infants; Levosimendan; Pediatric intensive care

Indexed keywords

CALCIUM SENSITIZER; CATECHOLAMINE; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN;

ACUTE HEART FAILURE; ADOLESCENT; ADULT; ARTICLE; BOLUS INJECTION; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INFUSION; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART VENTRICLE FAILURE; HEART VENTRICLE PERFORMANCE; HEMODYNAMIC MONITORING; HUMAN; INFANT; INTENSIVE CARE UNIT; MEAN ARTERIAL PRESSURE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CRITICAL ILLNESS; HUMANS; HYDRAZONES; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, PEDIATRIC; PYRIDAZINES; RETROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION;

EID: 33748648616     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000235251.14491.75     Document Type: Article

References (10)

1. Lohse MJ, Engelhardt S, Eschenhagen T: What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93:896-906
2. Edes I, Kiss E, Kitada Y, et al: Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77:107-113
3. Kopustinskiene DM, Pollesello P, Saris NE: Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001; 428:311-314
4. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360:196-202
5. Stocker CF, Shekerdemian LS, Norgaard MA, et al: Mechanisms of a reduced cardiac output, and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Crit Care Med 2006; In press
6. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81-86
7. Kivikko M, Antila S, Eha J, et al: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40:465-471
8. Nanas JN, Papazoglou PP, Terrovitis JV, et al: Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004; 94:1329-1332
9. Lilleberg J, Ylonen V, Lehtonen L, et al: The calcium sensitizer levosimendan and cardiac arrhythmias: An analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38:80-84
10. Luther YC, Schulze-Neick I, Stiller B, et al: Levosimendan-long-term inodilation in an infant with myocardial infarction. Z Kardiol 2004; 93:234-239